Anti-TNF treatment attenuates COVID-19 vaccine efficacy in IBD patients

IBD patients treated with infliximab have poor serological responses to a single dose of a SARS-CoV-2 vaccine, and should only be considered protected after two doses, UK researchers say. In a study of immunogenicity responses to Pfizer and AstraZeneca vaccines, investigators examined antibody responses and seroconversion rates in 865 infliximab-treated patients. Their findings, published in ...

Already a member?

Login to keep reading.

© 2021 the limbic